- Home
- YHGJ vs TENX Comparison
YHGJ vs TENX Comparison
Compare YHGJ & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YHGJ
- TENX
- Stock Information
- Founded
- YHGJ 1975
- TENX 1967
- Country
- YHGJ United States
- TENX United States
- Employees
- YHGJ N/A
- TENX N/A
- Industry
- YHGJ Specialty Chemicals
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- YHGJ Industrials
- TENX Health Care
- Exchange
- YHGJ Nasdaq
- TENX Nasdaq
- Market Cap
- YHGJ 22.0M
- TENX 19.5M
- IPO Year
- YHGJ 1997
- TENX N/A
- Fundamental
- Price
- YHGJ $0.59
- TENX $5.52
- Analyst Decision
- YHGJ
- TENX Strong Buy
- Analyst Count
- YHGJ 0
- TENX 4
- Target Price
- YHGJ N/A
- TENX $20.67
- AVG Volume (30 Days)
- YHGJ 10.0K
- TENX 67.4K
- Earning Date
- YHGJ 11-08-2024
- TENX 11-13-2024
- Dividend Yield
- YHGJ N/A
- TENX N/A
- EPS Growth
- YHGJ N/A
- TENX N/A
- EPS
- YHGJ N/A
- TENX N/A
- Revenue
- YHGJ $18,559,000.00
- TENX N/A
- Revenue This Year
- YHGJ N/A
- TENX N/A
- Revenue Next Year
- YHGJ N/A
- TENX N/A
- P/E Ratio
- YHGJ N/A
- TENX N/A
- Revenue Growth
- YHGJ 11.78
- TENX N/A
- 52 Week Low
- YHGJ $0.56
- TENX $2.77
- 52 Week High
- YHGJ $2.25
- TENX $27.36
- Technical
- Relative Strength Index (RSI)
- YHGJ 38.07
- TENX 52.17
- Support Level
- YHGJ $0.57
- TENX $5.70
- Resistance Level
- YHGJ $0.66
- TENX $6.01
- Average True Range (ATR)
- YHGJ 0.04
- TENX 0.48
- MACD
- YHGJ -0.00
- TENX -0.06
- Stochastic Oscillator
- YHGJ 18.18
- TENX 17.65
About YHGJ Yunhong Green CTI Ltd.
Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.